Chief operating officer, Alkermes
Appears in 1 story
Leads orexin strategy; identified 19 potential applications
Alkermes presented its orexin agonist as an ADHD treatment on September 21, the first time the new drug class has moved into a mainstream psychiatric market. The company calls the program a potential 'company changer.'
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
